Clinical trial NCT01938404: Octaplas Adult TTP Trial
Official title: Post-Marketing Requirement Study to Evaluate the Safety and Efficacy of Octaplas™ in Patients With Thrombotic Thrombocytopenic Purpura With Special Emphasis on Monitoring the Occurrence of Thromboembolic Events
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Thrombotic Thrombocytopenic Purpura
Keywords: Plasma exchange
Thrombotic Thrombocytopenic Purpura
TTP
Lead sponsor: Octapharma
Sponsor class: INDUSTRY
First posted: 2013-09-10
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult patients undergoing Plasma exchange for Thrombotic Thrombocytopenic Purpura

Brief summary: To assess and evaluate the safety of octaplas™ in comparison to standard plasma product (e.g., fresh frozen plasma (FFP) and other approved plasma products used within 24 hours of thawing) used in the treatment of TTP, in patients undergoing Therapeutic Plasma Exchange, with a special emphasis on the occurrence of thromboembolic events (TEEs).


Eligibility criteria: Inclusion Criteria:

1. Patient is a male or female at least 18 years of age or older.
2. Patient has a diagnosis of TTP or suspicion of TTP that is planned on being treated with TPE within 3 days of study entry.
3. Patient has thrombocytopenia (platelets \< 100 x 10P9P/L).
4. Patient is willing to give voluntary written informed consent before any study-related procedure is to be performed that is not part of standard medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care.

Exclusion Criteria:

1. Patient has a history of severe hypersensitivity reaction to plasma-derived products or to FFP.
2. Patient has an already known IgA deficiency with documented antibodies against IgA.
3. Patient is currently participating in an interventional clinical study or has participated during the past 1 month prior to study inclusion.
4. Patient has severe deficiencies of Protein S.
5. Patient received more than 1 treatment of plasma exchange or plasma infusion for current episode of TTP prior to randomization.
6. Patient is currently taking ACE-inhibitors; in case patient is under ACE-inhibitor treatment a wash-out period of at least 24 hours has to elapse prior the first plasma infusion.

Primary outcomes:
measure: The incidence of TEEs in patients receiving octaplas™ will be compared with the incidence rate in patients receiving plasma issued according to institutional standard of care.
timeFrame: Up to 28 days followed by a 24 hour follow-up
Secondary outcomes:
measure: Incidence of Citrate reactions during TPE based on clinical judgment of physician.
timeFrame: Up to 28 days followed by a 24 hour follow-up
measure: Incidence of Plasma-associated adverse reactions including Transfusion-Associated Circulatory Overload (TACO),
timeFrame: Up to 28 days followed by a 24 hour follow-up
measure: Incidence of Transfusion-Related Acute Lung Injury (TRALI)
timeFrame: Up to 28 days followed by a 24 hour follow-up
measure: Incidence of febrile reactions
timeFrame: Up to 28 days followed by a 24 hour follow-up
measure: Measurement of Safety laboratory parameters - International Normalized Ratio (INR)
timeFrame: Up to 28 days followed by a 24 hour follow-up
measure: Measurement of Prothrombin Time (PT)/Partial Thromboplastin Time (PTT).
timeFrame: Up to 28 days followed by a 24 hour follow-up
measure: Determination of overall clinical response (rating scale that takes into account platelet count, LDH levels, creatinine and neurological status).
timeFrame: Up to 28 days followed by a 24 hour follow-up
measure: measurement of Platelet count
timeFrame: Up to 28 days followed by a 24 hour follow-up
measure: measurement of hemoglobin
timeFrame: Up to 28 days followed by a 24 hour follow-up
measure: measurement of hematocrit
timeFrame: Up to 28 days followed by a 24 hour follow-up
measure: measurement of LDH.
timeFrame: Up to 28 days followed by a 24 hour follow-up
Other outcomes:
Locations:
city: Manhasset
country: United States
facility: Octapharma Study Site
state: New York
city: Rochester
country: United States
facility: Octapharma Study Site
state: New York
Study officials:
affiliation: International Medical Director
name: Wolfgang Frenzel
role: STUDY_DIRECTOR
References: